Pavan Kalyan B¹, Diana Nahakpam¹, DK Brahma²* and Rajesh Kumar M¹

¹PGTs of Department of Pharmacology, NEIGRIHMS, Shillong, India
²Additional Professor, Department of Pharmacology, NEIGRIHMS, Shillong, India

*Corresponding Author: DK Brahma, Additional Professor, Department of Pharmacology, NEIGRIHMS, Shillong, India.

Received: March 01, 2024; Published: March 06, 2024

Abstract

The advent of antibiotics during the 1940s revolutionized medicine, reducing mortality rates from infectious diseases. However, the emergence of antibiotic resistance presents a formidable global health threat, urging the search for new antimicrobial agents. The pipeline of new antibiotic research and development at present is very narrow and only a few antibiotics have been marketed over the last decades and they often resemble older, already known antibiotics. Traditional methods of antibiotic discovery have faced diminishing returns, leading to a shift towards target-based strategies, which have struggled to yield novel antibiotics. The recent discovery of clovibactin from previously uncultured soil bacteria represents a promising breakthrough in this arena. It exhibits potent bactericidal activity against a wide range of Gram-positive pathogens, including multidrug-resistant strains, with a distinctive mechanism of action targeting bacterial cell wall precursors. Additionally, it has demonstrated favorable pharmacokinetic properties and efficacy in animal models. Despite its potential, further investigation is necessary to evaluate its safety and clinical efficacy in the human population. Clovibactin brings a glimmer of hope in the ongoing battle against antibiotic resistance. Clovibactin is a promising discovery in fighting antibiotic-resistant pathogens and enhances its clinical usefulness.

Keywords: Clovibactin; Antibiotic Resistance; Gram-Positive Pathogens

References

1. Cook MA and Wright GD. “The past, present, and future of antibiotics”. Science Translational Medicine 657 (2022): eabo7793.
2. Buerger S., et al. “Microbial scout hypothesis and microbial discovery”. Applied and Environmental Microbiology 9 (2012): 3229-3233.
3. Fage CD., et al. “The Kalimantacin Polyketide Antibiotics Inhibit Fatty Acid Biosynthesis in Staphylococcus aureus by Targeting the Enoyl-Acyl Carrier Protein Binding Site of FabI”. Angewandte Chemie International Edition 26 (2020): 10549-10556.
4. Fernández-Martínez L and Bibb M. “Use of the Meganuclease I-SceI of Saccharomycescerevisiae to select for gene deletions in actinomycetes”. Scientific Report 4 (2014): 7100.
5. Shukla R., et al. “A new antibiotic from an uncultured bacterium binds to an immutable target”. bioRxiv (2023).
6. Hsu ST., et al. “The nisin–lipid II complex reveals a pyrophosphate cage that provides a blueprint for novel antibiotics”. Nature Structural and Molecular Biology 11 (2004): 963-967.
7. Lebreton F., et al. “Tracing the Enterococci from Paleozoic Origins to the Hospital”. Cell 169 (2017): 849-861e813.
8. Antimicrobial Resistance Collaborators. “Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis”. Lancet 399 (2022): 629-655.

Citation

Citation: DK Brahma., et al. “A Beacon of Hope in the Battle Against Antimicrobial Resistance".Acta Scientific Pharmaceutical Sciences 8.4 (2024): 53-56.

Copyright

Copyright: © 2024 DK Brahma., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.